Cargando…

Ansuvimab: First Approval

Ansuvimab (ansuvimab-zykl; EBANGA™) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) to block its entry into host cells. Ansuvimab has been recently approved in the USA for the treatment of infection caused by Z....

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983082/
https://www.ncbi.nlm.nih.gov/pubmed/33751449
http://dx.doi.org/10.1007/s40265-021-01483-4
_version_ 1783667845394071552
author Lee, Arnold
author_facet Lee, Arnold
author_sort Lee, Arnold
collection PubMed
description Ansuvimab (ansuvimab-zykl; EBANGA™) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) to block its entry into host cells. Ansuvimab has been recently approved in the USA for the treatment of infection caused by Z. ebolavirus in adult and paediatric patients, including in neonates born to a mother who is RT-PCR positive for Z. ebolavirus infection, following the results of the PALM phase II/III trial. This article summarizes the milestones in the development of ansuvimab leading to this first approval for the treatment of infections caused by Ebola virus in adults and paediatric patients.
format Online
Article
Text
id pubmed-7983082
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79830822021-03-23 Ansuvimab: First Approval Lee, Arnold Drugs AdisInsight Report Ansuvimab (ansuvimab-zykl; EBANGA™) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) to block its entry into host cells. Ansuvimab has been recently approved in the USA for the treatment of infection caused by Z. ebolavirus in adult and paediatric patients, including in neonates born to a mother who is RT-PCR positive for Z. ebolavirus infection, following the results of the PALM phase II/III trial. This article summarizes the milestones in the development of ansuvimab leading to this first approval for the treatment of infections caused by Ebola virus in adults and paediatric patients. Springer International Publishing 2021-03-22 2021 /pmc/articles/PMC7983082/ /pubmed/33751449 http://dx.doi.org/10.1007/s40265-021-01483-4 Text en © Springer Nature Switzerland AG 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle AdisInsight Report
Lee, Arnold
Ansuvimab: First Approval
title Ansuvimab: First Approval
title_full Ansuvimab: First Approval
title_fullStr Ansuvimab: First Approval
title_full_unstemmed Ansuvimab: First Approval
title_short Ansuvimab: First Approval
title_sort ansuvimab: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983082/
https://www.ncbi.nlm.nih.gov/pubmed/33751449
http://dx.doi.org/10.1007/s40265-021-01483-4
work_keys_str_mv AT leearnold ansuvimabfirstapproval